Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469916 | 1.00 | PRMT5 (0.38) | PRMT5TRPA1WDR77HTR7NR1H2 | |
| SCHEMBL25918144 | 0.92 | PRMT5 (0.39) | PRMT5WDR77 | |
| SCHEMBL30551268 | 0.92 | SLC6A9 (0.36) | PRMT5WDR77NR1H2NR1H3 | |
| SCHEMBL25321058 | 0.92 | SLC6A9 (0.36) | PRMT5WDR77NR1H2NR1H3 | |
| SCHEMBL30551486 | 0.89 | L3MBTL1 (0.36) | PRMT5WDR77NR1H2NR1H3 | |
| SCHEMBL25318283 | 0.89 | L3MBTL1 (0.36) | PRMT5WDR77NR1H2NR1H3 | |
| SCHEMBL24365599 | 0.86 | PRMT5 (0.39) | PRMT5TRPA1WDR77HTR7 | |
| SCHEMBL25918094 | 0.86 | PRMT5 (0.41) | PRMT5WDR77 | |
| SCHEMBL25321812 | 0.84 | RIPK1 (0.46) | PRMT5WDR77 | |
| SCHEMBL25321815 | 0.84 | RIPK1 (0.46) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PRMT5 347/4885TRPA1 848/4885WDR77 1263/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PRMT5 347/4885TRPA1 848/4885WDR77 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.